New considerations in the medical management of early Parkinson's disease: Impact of recent clinical trials on treatment strategy

Parkinsonism and Related Disorders

Volumn 15, Issue SUPPL. 3, 2009, Pages

  Hauser, Robert A ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Levodopa; Parkinson's disease; Pramipexole; Rasagiline; Ropinirole; Selegiline; Treatment

Indexed keywords

ANTIPARKINSON AGENT; BROMOCRIPTINE; CABERGOLINE; CARBIDOPA PLUS LEVODOPA; DOPAMINE RECEPTOR STIMULATING AGENT; IPX 066; LEVODOPA; MONOAMINE OXIDASE B INHIBITOR; PERGOLIDE; PLACEBO; PRAMIPEXOLE; RASAGILINE; ROPINIROLE; SELEGILINE; UNCLASSIFIED DRUG; XP 21279;

ARTICLE; BINGE EATING DISORDER; BRADYKINESIA; CLINICAL TRIAL; COGNITIVE DEFECT; COMORBIDITY; COMPULSION; DISEASE SEVERITY; DOPAMINERGIC SYSTEM; DRUG ABSORPTION; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSKINESIA; EARLY INTERVENTION; EDEMA; HALLUCINATION; HUMAN; IMPULSE CONTROL DISORDER; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MOTOR DYSFUNCTION; MUSCLE RIGIDITY; PARKINSON DISEASE; PARKINSONISM; PATHOLOGICAL GAMBLING; PERIPHERAL EDEMA; PRIORITY JOURNAL; QUALITY OF LIFE; SEXUAL BEHAVIOR; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; SUSTAINED RELEASE FORMULATION; SYMPTOM; THERAPY DELAY; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TREATMENT OUTCOME; TREMOR;

ANTIPARKINSON AGENTS; DOPAMINE AGENTS; HUMANS; IMPULSE CONTROL DISORDERS; MONOAMINE OXIDASE INHIBITORS; PARKINSON DISEASE;

EID: 71849114385     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1353-8020(09)70772-2     Document Type: Article

References (27)

1. Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 321 (1989) 1364-1371
2. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol 59 (2002) 1937-1943
3. Pålhagen S., Heinonen E., Hägglund J., Kaugesaar T., Mäki-Ikola O., Palm R., and Swedish Parkinson Study Group. Selegiline slows the progression of the symptoms of Parkinson disease. Neurology 66 (2006) 1200-1206
4. Pålhagen S., Heinonen E.H., Hägglund J., et al. Selegiline delays the onset of disability in de novo parkinsonian patients. Neurology 51 (1998) 520-525
5. Larsen J.P., Boas J., and Erdal J.E. Does selegiline modify the progression of early Parkinson's disease? Results from a five-year study. The Norwegian-Danish Study Group. Eur J Neurol 6 (1999) 539-547
6. Przuntek H, Conrad B, Dichgans J, et al. SELEDO: a 5-year long-term trial on the effect of selegiline in early Parkinsonian patients treated with levodopa. Eur J Neurol; 6:141-50.
7. Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 61 (2004) 561-566
8. Hauser R.A., Lew M.F., Hurtig H.I., Ondo W.G., Wojcieszek J., Fitzer-Attas C.J., and TEMPO Open-label Study Group. Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease. Mov Disord 24 (2009) 564-573
9. Olanow C.W., Rascol O., Hauser R., et al., ADAGIO Study Investigators. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 361 (2009) 1268-1278
10. Antonini A., Tolosa E., Mizuno Y., Yamamoto M., and Poewe W.H. A reassessment of risks and benefits of dopamine agonists in Parkinson's disease. Lancet Neurol 8 (2009) 929-937
11. Rascol O., Brooks D.J., Korczyn A.D., De Deyn P.P., Clarke C.E., Lang A.E., and 056 Study Group. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med 342 (2000) 1484-1491
12. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. JAMA 284 (2000) 1931-1938
13. Holloway R.G., Shoulson I., Fahn S., et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 61 (2004) 1044-1053
14. Oertel W.H., Wolters E., Sampaio C., et al. Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study. Mov Disord 21 (2006) 343-353
15. Bracco F., Battaglia A., Chouza C., et al. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study. CNS Drugs 18 (2004) 733-746
16. Parkinson Study Group CALM Cohort Investigators. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease. Arch Neurol 66 (2009) 563-570
17. Hauser R.A., Rascol O., Korczyn A.D., et al. Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. Mov Disord 22 (2007) 2409-2417
18. Lees A.J. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom. BMJ 311 (1995) 1602-1607
19. Lees A.J., Katzenschlager R., Head J., and Ben-Shlomo Y. Ten-year follow-up of three different initial treatments in de-novo PD: a randomized trial. Neurology 57 (2001) 1687-1694
20. Katzenschlager R., Head J., Schrag A., Ben-Shlomo Y., Evans A., Lees A.J., and Parkinson's Disease Research Group of the United Kingdom. Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD. Neurology 71 (2008) 474-480
21. Weintraub D, Koester J, Potenza MN, Siderowf AD, Stacy MA, Whetteckey J, et al.; for the DOMINION Study Group. Dopaminergic therapy and impulse control disorders in Parkinson's disease: a cross-sectional study of over 3,000 patients. Paper presented at: The Movement Disorder Society's 12th International Congress of Parkinson's Disease and Movement Disorders; 22-26 June 2008, Chicago, IL, USA.
22. Parkinson Study Group. Levodopa and the progression of Parkinson's disease. N Engl J Med 351 (2004) 2498-2508
23. Hauser RA, Auinger P, Oakes D; on behalf of the Parkinson Study Group. Levodopa response in early Parkinson's disease. Mov Disord 2009; in press.
24. Olanow C.W., Obeso J.A., and Stocchi F. Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol 5 (2006) 677-687
25. Hauser R.A. Levodopa: past, present, and future. Eur Neurol 62 (2009) 1-8
26. Goole J., Deleuze P., Vanderbist F., and Amighi K. New levodopa sustained-release floating minitablets coated with insoluble acrylic polymer. Eur J Pharm Biopharm 68 (2008) 310-318
27. Di Stefano A., Sozio P., and Cerasa L.S. Antiparkinson prodrugs. Molecules 13 (2008) 46-68